Botulinum Toxin Type B for Type A Resistant Bladder Spasticity

Pistolesi, Donatella; Selli, Cesare; Rossi, Bruno; Stampacchia, G.

doi:10.1097/01.ju.0000108844.10235.f1

Cited by 55 publications

(16 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This data served as one rationale for the investigation of BTX-B in the treatment of urologic disorders. The use of BTX-B for DO has been reported in de novo patients, those with documented BTX-A resistance, and in a cross-over investigation protocol (42)(43)(44)(45)(46). Subjective and objective improvement was seen in all studies.…”

Section: Repeat Injectionmentioning

confidence: 79%

Botulinum toxin injection: a review of injection principles and protocols

2007

View full text Add to dashboard Cite

Despite the favorable outcomes seen using botulinum toxin (BTX) for voiding dysfunction using BTX, a standardized technique and protocol for toxin injection is not defined. We reviewed the current literature on intravesical BTX injection for DO (detrusor overactivity). Specific attention was placed on defining optimal injection protocol, including dose, volume, and injection sites. In addition, we sought to describe a standard technique to BTX injection.

show abstract

Section: Repeat Injectionmentioning

confidence: 79%

Botulinum toxin injection: a review of injection principles and protocols

2007

View full text Add to dashboard Cite

show abstract

“…Recently, three cases have been published of patients with NDO with clinically suspected and electrophysiologically proven resistance to botulinum toxin-A [Pistolesi et al, 2004;Reitz et al, 2004]. These patients then received intradetrusal injections of botulinum toxin-B (Neurobloc, Elan Pharma International Ltd., Dublin, Ireland) with successful outcome.…”

Section: Side Effects Of Botulinum Toxinmentioning

confidence: 96%

Botulinum toxin for the treatment of lower urinary tract symptoms: A review

Sahai

Khan

Fowler

et al. 2004

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

“…Il est proposé que le rythme des consultations de suivi soit dicté par la réponse clinique du patient en raison du caractère fonctionnel de l'indication n'exposant pas ce patient neurologique à un préjudice uronéphrologique ou général, de l'absence d'argument en faveur de l'épuisement de l'efficacité thérapeutique au fil des réinjections [19] et de la rareté des phénomènes d'immunisation antitoxine botulique A [20,21].…”

Section: éValuation Postthérapeutique Après Injection Répétée De Toxiunclassified